China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference

China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) (“China Biologic,” or the “Company”), a leading plasma-based biopharmaceutical company in China, today announced that the Company’s management will present at the upcoming Brean Murray, Carret & Co. 2010 China Growth Conference.

The Brean Murray, Carret & Co. 2010 China Growth Conference is a two-day conference (November 17-18, 2010) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. China Biologic’s management will be available for 1x1 meetings before and after the Company’s presentation.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the “Company”), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biological Technologies Co., Ltd, and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical company in China. The Company is a fully integrated biological products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

SOURCE China Biologic Products, Inc.